SCIESCOPUSQ1
Alzheimers Research & Therapy
BMC, United Kingdom
Alzheimers Research & Therapy is an academic journal published by BMC (United Kingdom). Identifiers: eISSN 1758-9193. Indexed in SCIE, SCOPUS. Metrics: JIF 7.6, CiteScore 13.0, SJR 2.709, SNIP 1.76. Subject areas: CLINICAL NEUROLOGY, NEUROSCIENCES. tlooto lists 3,113 papers from this journal.
CiteScore
13.00
Scopus citation metric
SJR
2.709
SCImago rank
SNIP
1.76
Source normalized impact
Percentage rank
-
JIF percentile rank
Journal profile
- ISSN
- -
- eISSN
- 1758-9193
- Abbreviation
- ALZHEIMERS RES THER
- Publisher
- BMC
- Country
- United Kingdom
Web of Science categories
SCIECLINICAL NEUROLOGY, NEUROSCIENCES
Scopus ASJC categories
2728 Neurology (clinical)2805 Cognitive Neuroscience2808 Neurology
Keywords
Clinical Neurology | Neurosciences
Papers in this journal
Recent papers
- T1-weighted/T2-weighted ratio reflects microstructural changes in Alzheimer's disease.
2026
- Are diagnostic technologies for alzheimer’s disease and dementia cost-effective? A systematic review of economic evaluations
2026
- Circulating inflammatory proteins predict dementia risk, and are linked to structural brain changes and modifiable risk factors
2026
- Prospective study on clinical utility of plasma p-Tau217 and other biomarkers in Japanese memory clinics using the LUMIPULSE platform
2026 · 2 citations
- Associations of white matter hyperintensity regression and progression with cognitive and structural brain changes: a population-based cohort study
2026
Most cited papers
- Mitochondrial dysfunction - the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid-β toxicity
2011 · 2,609 citations
- Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
2014 · 1,629 citations
- Recent global trends in the prevalence and incidence of dementia, and survival with dementia
2016 · 750 citations
- Repurposed agents in the Alzheimer’s disease drug development pipeline
2020 · 734 citations
- A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
2020 · 682 citations